MEDICAL MANAGEMENT OF RADIOLOGICAL CASUALTIES

Victims of radiological terrorism events require prompt diagnosis and treatment of medical and surgical conditions as well as conditions related to radiation exposure. Hospital emergency personnel should triage victims using traditional medical and trauma criteria. Radiation dose can be estimated early post-event using rapid-sort, automated biodosimetry and clinical parameters such as the clinical history, the time to emesis (TE), and lymphocyte depletion kinetics. For TE < 2 h, the effective whole-body dose is at least 3 Gy. If TE < 1 h, the whole-body dose most probably exceeds 4 Gy. Lymphocyte depletion follows dose-dependent, first order kinetics after high-level gamma and criticality incidents. Patient radiation dose can be estimated very effectively from the medical history, serial lymphocyte counts, and TE, and subsequently confirmed with chromosome-aberration bioassay, the current gold standard. These data are effectively analyzed using the Armed Forces Radiobiology Research Institute Biodosimetry Assessment Tool. The medical management of patients with acute, moderate to severe radiation exposure (effective whole-body dose >3 Gy) should emphasize the rapid administration of colony stimulating factors. All of these compounds decrease the duration of radiation-induced neutropenia and stimulate neutrophil recovery, albeit with some variability, in patients who have received myelotoxic chemotherapy, and all have demonstrated benefit in irradiated animals. For those patients developing febrile radiation-induced neutropenia, adherence to the current Infectious Diseases Society of America guidelines for high-risk neutropenia is recommended.

[1]  A. Schaffner,et al.  Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. , 1995, The Journal of infectious diseases.

[2]  I. Brook,et al.  Quinolone therapy of Klebsiella pneumoniae sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin. , 1990, Radiation research.

[3]  H. Deeg,et al.  Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. , 1994, Blood.

[4]  M. Paesmans,et al.  Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1994, JAMA.

[5]  R. Leonard,et al.  Emergency department radiation accident protocol. , 1980, Annals of emergency medicine.

[6]  I. Brook,et al.  Management of postirradiation sepsis. , 2002, Military medicine.

[7]  I. Brook,et al.  Ofloxacin and penicillin G combination therapy in prevention of bacterial translocation and animal mortality after irradiation , 1991, Antimicrobial Agents and Chemotherapy.

[8]  C. Mengoli,et al.  Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[10]  E. Bow,et al.  Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Blajchman Immunomodulation and Blood Transfusion , 2002, American journal of therapeutics.

[12]  B. Lichtiger,et al.  Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. , 2001, Haematologica.

[13]  D. Coyle,et al.  Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. , 2003, JAMA.

[14]  A. Vorobiev Acute radiation disease and biological dosimetry in 1993 , 1997, Stem cells.

[15]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[16]  S. J. Baum,et al.  Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. , 1989, Health physics.

[17]  E. Cronkite,et al.  Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction. , 1995, Experimental hematology.

[18]  C. Lushbaugh,et al.  THE IMPORTANCE OF DOSIMETRY TO THE MEDICAL MANAGEMENT OF PERSONS ACCIDENTALLY EXPOSED TO HIGH LEVELS OF RADIATION , 1965 .

[19]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[20]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.

[21]  J. Lau,et al.  Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Deeg,et al.  Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. , 1993, Blood.

[23]  James Armitage,et al.  Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group , 2004, Annals of Internal Medicine.

[24]  Baranov Ae,et al.  Diagnosis, Clinical Picture and Treatment of the Acute Radiation Disease in Chernobyl Accident Victims , 1989 .

[25]  T. Priestman Clinical studies with ondansetron in the control of radiation-induced emesis. , 1989, European journal of cancer & clinical oncology.

[26]  R. Goans,et al.  Early dose assessment in criticality accidents. , 2001, Health physics.

[27]  I. Brook,et al.  Quinolone therapy in the prevention of endogenous and exogenous infection after irradiation. , 1994, The Journal of antimicrobial chemotherapy.

[28]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[29]  D. V. Bekkum Radiation sensitivity of the hemopoietic stem cell. , 1991 .

[30]  E. Bow,et al.  Randomized Placebo-Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy , 1999 .

[31]  N. Wald,et al.  Radiation accidents with multi-organ failure in the United States , 2005 .

[32]  Nicholas Dainiak,et al.  The hematologist and radiation casualties. , 2003, Hematology. American Society of Hematology. Education Program.